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Humanat plasticity in response to altered activity levels, ultimately resulting in tissue
remodelling and substantial changes in mass. Animal research would suggest that the ubiquitin proteasome
system, in particular the ubiquitin ligases MAFbx/atrogin-1 and MuRF1, are instrumental to the processes
underlying these changes. This review article therefore examines the role of proteasomal-mediated protein
degradation in human skeletal muscle in health and disease. Speciﬁcally, the effects of exercise, disuse and
inﬂammatory disease states on the ubiquitin proteasome system in human skeletal muscle are examined.
The article also identiﬁes several inconsistencies between published human studies and data obtained from
animal models of muscle atrophy, highlighting the need for a more comprehensive examination of the
molecular events responsible for modulating muscle mass in humans.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe dynamic adaptation of skeletal muscle to changing require-
ments has been acknowledged for decades, but the molecular events
underpinning these adaptations have only just started to become
clearer. Intricately regulated anabolic and catabolic pathways are
responsible for the maintenance of muscle protein content, which
represents the bulk of skeletal muscle mass, and imbalance between
these pathways results in a change inmusclemass that can sometimes
be rapid. Classically, increases in skeletal muscle mass have been
associated with individuals partaking in resistance exercise programs
[1] or after the administration of anabolic agents, such as testosterone
[2,3]. Conversely, a loss of muscle mass has been observed following
disuse [4–6] and a number of disease states, including but not limited
to; sepsis [7], cancer cachexia [8,9], AIDS [8], diabetes mellitus [9,10]
and renal failure [11,12], with sometimes rapid onset and profound
consequences.
In eukaryotic cells, four main mechanisms are responsible for
the majority of cellular protein degradation, mediated via the
actions of either cysteine-dependent aspartate speciﬁc proteases
(caspases) [13,14], cathepsins [15], calcium-dependent calpains
[16,17], or the ubiquitin proteasome system (UPS) [18,19]. A
substantial body of evidence has accumulated implicating the UPS
as the principal regulator of skeletal muscle atrophy [20]. This has
led many researchers to focus on both the components and
regulators of the UPS in skeletal muscle, with the hopes of: +44 0 115 823 0142.
A.J. Murton).
ll rights reserved.providing a greater understanding of the mechanisms responsible
for increased skeletal muscle protein degradation, and identifying
clinically relevant therapeutic targets to ablate disease-induced
muscle atrophy.
To date, the vastmajority of the information about themechanisms
responsible for muscle atrophy has been obtained from cell line and
small mammal (primarily rodents) based research, with limited
information coming to light concerning the molecular mechanisms
modulating skeletal muscle mass in humans. Whilst the similarity in
organ systems, systemic physiology and genes between the rodent
and human species is useful, the validity of information obtained from
non-human studies needs to be questioned when considering their
direct relevance to human situations of muscle hypertrophy/atrophy.
Indeed, several reported observations give rise to this stance. Firstly,
most studies utilise animals that are immature and still growing,
where high rates of muscle protein synthesis, low metabolic stability
(i.e. a weak capacity to maintain homeostasis) and a comparatively
high basal metabolic rate are commonly observed [21]. In contrast,
most human studies involve subjects of adult age where, in the
absence of pathological events, display body weights that are
effectively stable for months at a time, experience high metabolic
stability, and have much lower speciﬁc metabolic rates that include
lower rates of muscle protein turnover. Speciﬁc to skeletal muscle, the
response of the processes governing muscle protein synthesis to
insulin differs between rodents and humans, notably where insulin,
even at supraphysiological doses, fails to augment muscle protein
synthesis in humans without prior amino acid administration [22,23].
These observations, in conjunction with the discrepancies of both the
stress response to experimental procedures and the general severity
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studies conducted in informed, consenting, human adults, provides
some cause for concern when translating cell-line/animal data to the
human situation.
Nevertheless, ﬁndings from cell line, animal and human based
research, has consistently pointed to the UPS as a pivotal component
to the instigation and regulation of muscle protein breakdown.
However, to date, a comprehensive examination of the literature
pertaining to the regulation of the UPS in modulating human skeletal
muscle mass, particularly in regard to the effects of exercise and
disease, has not been undertaken. In this review article therefore, we
will ﬁrst outline the proposed involvement of the UPS in muscle
atrophy, as discovered in cell lines and small animals. This will be
followed by a detailed examination of published studies investigating
the effects of exercise on the UPS pathways in human skeletal muscle.
Subsequently, conditions that favour muscle atrophywill be examined
and discussed, including the use of exercise to modulate the atrophic
response of catabolic disease states.Fig. 1. UPS mediated protein degradation. Diagrammatical representation of the UPS detailin
four Ub monomers in a chain, covalently attached by lysine 76, is sufﬁcient for entry into, a
recycled via the action of the deubiquitinating enzymes.2. The muscle atrophy ‘program’
The increased expression of UPS constituents, including compo-
nents of the 26S proteasome itself, and the prevention of increased
proteolysis in atrophic conditions via the use of proteasome inhibitors
[24–26], has ledmany to conclude that the UPS is intrinsically linked to
the degradation ofmyoﬁbril proteins in skeletalmuscle [27]. Of note, it
has been shown that the UPS is unable to degrade intact myoﬁbrils
[28], suggesting that an alternative system is responsible for initial
myoﬁbril disruption, possibly the result of increased caspase-3 [13] or
calpain activity [29]. The UPS is an ATP-dependent proteolytic system
that involves the degradation of target proteins, with substrates
identiﬁed for degradation by the addition of ubiquitin (Ub) molecules,
a process itself coordinated via the activity of a triplet of enzymes [30].
Ubiquitin transfer to targeted proteins represents a robust method for
the speciﬁc targeting of protein families. In brief, Ub is ﬁrst bound to
the Ub-activating enzyme (E1) via a high-energy thioester bond in an
ATP-dependent process (Fig. 1). Ubiquitin is subsequently transferredg the activation and conjugation of free Ub onto Ub-ligase targeted proteins. Addition of
nd subsequent degradation by, the 26S proteasome. Ubiquitin chains are subsequently
732 A.J. Murton et al. / Biochimica et Biophysica Acta 1782 (2008) 730–743from the Ub-activating enzyme to the Ub-conjugating enzyme (E2) via
the formation of a new thioester linkage between Ub and a cysteine
residue of the E2 enzyme. Generally, albeit with a few notable
exceptions [31,32], the Ub monomer, catalysed by the action of an
Ub-ligase enzyme (E3), is conjugated to the target protein via an
isopeptide bond between the ɛ-amino group of a lysine residue in the
target protein and the carboxy-terminal glycine residue 76 in Ub (for a
review see [30]). The process is repeated until a minimum of four Ub
monomers are covalently attached via lysine residue 48 of Ub to the
target protein, the classical formation that is recognised by the 26S
proteasome as a signal to degrade the target protein [33].
In eukaryotic cells, only one Ub-activating enzyme has been
characterised and, observed in relatively high abundance, it meets the
somewhat-divergent demands placed upon it by the UPS [34,35].
Indeed, even under normal physiological conditions, the UPS is
constantly degrading damaged or malformed proteins [36], so as to
maintain normal cell function. In humans, several dozens of Ub-
conjugating enzymes are also present, in addition to hundreds of Ub-
ligases [37], through which target speciﬁcity is established.
Following successful ubiquitination, and only once the criterion for
recognition by the 26S proteasome has been met, proteins are
unfolded and fed into the proteasome in an ATP-dependent process
[19]. The 26S proteasome consists of a 20S catalytic core and 19SFig. 2. AKT regulated signalling events. Representation of the effects of anabolic stimuli on
pathways and events that are increased and decreased, respectively, following AKT activatioregulatory caps. Structurally, the 20S proteasome consists of four
heptameric rings, formed from alpha subunits providing structural
support [38], and the beta subunits responsible for the chymotrypsin-
like, trypsin-like and caspase-like activities (for a comprehensive
review see [39]). The proteasome cleaves tagged proteins into short
oligonucleotides, after which the activity of tripeptidyl-peptidase II
and exopeptidases result in almost complete degradation of the
original protein [40].
In 2001, the mRNAs for twomuscle-speciﬁc Ub-ligases were found
to be elevated in the atrophied muscles of food-deprived mice [41]
and limb immobilised rats [42]. These two Ub-ligases, MAFbx/atrogin-
1 and MuRF1, were collectively termed ‘atrogins’ and increased mRNA
levels for both were subsequently observed in various animal models
of muscle atrophy, including but not limited to; burn injury [43],
uremia [44], diabetes mellitus [44], denervation [42], unweighting
[4,44], dexamethasone administration [45,46] and sepsis [49,50].
Moreover, when knocked out, MAFbx/atrogin-1−/− and MuRF1−/− mice
appeared resistant to the effects of denervation-induced muscle
atrophy, with a 56% and 36% respective sparing of muscle loss,
compared to littermate controls [42]. Consistent with these ﬁndings, it
was suggested that MAFbx/atrogin-1 and MuRF1 may, in part, be
responsible for the UPS mediated muscle protein degradation
observed during muscle atrophy conditions [47].AKT mediated signalling events in skeletal muscle. Blue and red colouring highlights
n (phosphorylation).
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MAFbx/atrogin-1 and MuRF1 Ub-ligases are intrinsically linked to both
cellular metabolic status and inﬂammatory state via a coordinated
pathway of signalling events. Li and colleagues discovered that both
H2O2 and the catabolic cytokine tumor necrosis factor-alpha (TNFα),
were competent inducers of MAFbx/atrogin-1 mRNA expression in ske-
letal muscle [48]. Moreover, they observed that TNFα induced ex-
pression of MAFbx/atrogin-1 mRNA was blunted by the p38 MAPK
inhibitors SB203580 and curcumin, suggesting that TNFα works via a
p38 MAPK dependent mechanism to stimulate MAFbx/atrogin-1
expression [49]. At about the same time, Cai and colleagues, with the
use of constitutively active IκK mice (termed MIKK mice), showed an
activation of NF-κB leads to an elevation in MuRF1, but not MAFbx/
atrogin-1, mRNA [50]. Additionally, in the tibialis anterior of MIKKmice,
both ﬁbre diameter and ﬁbre cross sectional area were reduced to 56%
and 32% respectively, compared to control mice [50]. Moreover, MIKK
mice crossed with MuRF1−/− mice experienced a 50% rescue of protein
degradation [50], thus demonstrating that NF-κB mediated protein
degradation is heavily dependent on the upregulation of theMuRF1 Ub-
ligase. Collectively, these ﬁndings highlight that the transcriptional
regulation of MAFbx/atrogin-1 and MuRF1 are sensitive to local
inﬂammatory mediators (TNFα) and the NF-κB inﬂammatory pathway
itself. Furthermore, they showMAFbx/atrogin-1 andMuRF1 to be able to
function independently of each other.
Transcription of the MAFbx/atrogin-1 and MuRF1 genes also
appear under the control of the forkhead Foxo family of transcription
factors. It had been known for some time that transgenic over-
expression of Foxo1 resulted in an atrophic phenotype [51]. Likewise,
elevations in the forkhead transcription factors have been observed in
muscle of animals subjected to starvation, glucocorticoid administra-
tion, diabetes, uremia and cancer [44,52]. The Foxo family of
transcription factors are rendered inactive as a result of phosphoryla-
tion by AKT (also known as protein kinaseB) which results in the
removal of the transcription factors from the nucleus where they are
subsequently sequestered in the cytoplasm [53]. AKT represents an
important mediator of the protein synthesis initiation pathway and is
responsible for regulating the formation of the 43S preinitiation
complex via GSK3β inhibition, synthesis of ribosomal proteins, and
binding of the terminal 7-methylguanosine mRNA cap to the eIF4F
complex via mTOR activation (Fig. 2; for a comprehensive review see
[54]). Consequently, as the Foxo1 transcription factor is also known to
increase the transcription of pyruvate dehydrogenase kinase isoform 4
[52,55], a reversible inhibitor of the pyruvate dehydrogenase complex
[56], and thus a regulator of the decarboxylation of pyruvate to acetyl-
CoA in the TCA cycle, the regulation of MAFbx/atrogin-1 and MuRF1
mRNA expression by Foxo forkhead transcription factors appears
intrinsically linked to the rate of muscle protein synthesis and cellular
oxidative metabolism. In support, our group has recently shown
lipopolysaccharide-induced endotoxaemia to result in the coordi-
nated reductions of AKT protein levels and cytosolic phosphorylation
of Foxo1 and Foxo3. These observations were accompanied by
signiﬁcant increases in MAFbx/atrogin-1 and PDK4 protein levels
and signiﬁcant reductions in muscle protein content and pyruvate
dehydrogenase complex activity in rodent fast-twitch muscle leading
to an impairment of carbohydrate oxidation [57]. To clarify, during
times of increased muscle protein synthesis, it would be hypothesised
that MAFbx/atrogin-1 and MuRF1 mRNA expression would be
suppressed, and vice versa. However, as discussed in detail later, in
humans this relationship is not consistently observed.
3. Exercise and the UPS in human skeletal muscle
3.1. Eccentric contraction induced muscle “damage” and remodelling
Exercise, an essential component of a healthy and balanced
lifestyle, elicits substantial metabolic and functional demands uponskeletal muscle in humans. The nature of these demands depends
greatly upon the mode, intensity and duration of the exercise [58]. A
number of human studies have examined the role of the UPS in
skeletal muscle hypertrophy/remodelling following eccentric and
concentric contractions and, to a lesser degree, endurance exercise.
While either unaccustomed eccentric or concentric exercise elevates
levels of both fractional protein synthesis rates and fractional protein
breakdown rates [59], the cellular and subsequent morphological
changes in response to the two exercise stimuli appear somewhat
divergent. Unaccustomed or intense eccentric exercise has been
associated with signiﬁcant muscle damage, characterised by localised
muscular pain, inﬂammation [60], extensive sarcomere disruption, z-
disk streaming [61,62] and increased serum creatine kinase activity
[63] and troponin I levels [64,65]. Concomitant with a rise in
myoﬁbrillar damage and inﬂammation/pain, muscle strength can be
reduced by 50%, with a gradual recovery over the 5–10 day period
post-exercise [66,67]. Conversely, whilst a single bout of concentric
resistance exercise in untrained subjects can also induce myoﬁbrillar
disruption, the degree of damage is far more limited than that of
eccentric exercise [67]. However, it should be noted that mild
eccentric and concentric exercise displays only limited damage and,
moreover, evidence suggests that eccentric loading is important for
maximising the hypertrophic response to resistance training [68,69].
Biopsies obtained form the vastus lateralis of healthy male subjects
24 h after completing an intense eccentric exercise protocol show
increased proportions of myoﬁbrillar disruption compared to samples
taken immediately post exercise [70]. Thus, a progression of the
exercise induced muscle damage is dependent not only on the initial
mechanical stress, but also on post-exercise events [70]. Consistent
with this suggestion, an elevation in themRNA and protein expression
of free Ub and components of the 20S proteasome in skeletal muscles
of subjects following a single bout of eccentric exercise, in addition to
increased levels of Ub conjugated proteins 48 h post exercise (Table 1),
strongly suggest that the UPS may play a part in eccentric contraction
inducedmuscle damage. A sole report demonstrating no change in the
amount of Ub-conjugated proteins following eccentric exercise was
potentially due to an insufﬁcient period of time between the exercise
intervention and the period of measurement (24 h; [71]).
The induction of the UPS during eccentric contraction induced
muscle damage appears instrumental in the remodelling of the
skeletal muscle myoﬁlaments; tentatively instigated to limit skeletal
muscle damage from future eccentric bouts. Indeed, the degree of
muscle damage associated with the original bout of eccentric exercise
is attenuated following a second bout performed several weeks after
the ﬁrst [72,73]. Thus, adaptations must have occurred to limit the
muscle ﬁbre susceptibility to mechanical stress [67]. Suggested
remodelling events include the addition of sarcomeres in series,
resulting in shorter average sarcomere length, altered motor until
recruitment patterns [74], and an increase in desmin protein levels
resulting in a putative enhancement of z-disk stability [70]. Moreover,
elevated levels of skeletal muscle heat shock protein's HSP27 and
HSP72 have been observed following eccentric exercise [70,75,76].
The heat shock proteins represent a family of molecular chaperones;
being expressed at times of cellular stress, they are responsible for
both the maintenance of protein structure and orchestrating the
repair of malformed/damaged proteins. As a consequence, heat shock
proteins are considered to have anti-proteolytic and anti-apoptotic
effects [77]. Collectively, this appears tantamount to the skeletal
muscle cell trying to preserve function during a period of increased
damage/remodelling elicited by exercise, which is dependent upon
intensity [78].
The role of the UPS in the initiation of the ‘protective repeated bout
effect’ is less clear. While it had been hypothesised that a reduction in
UPS mediated proteolysis of myoﬁbrillar proteins would be expected
following subsequent bouts of eccentric exercise performed several
weeks apart, presumably because sarcomeric remodelling had already
Table 1
Exercise and the UPS
Measured component Time point(s) measured Intervention Study
Eccentric exercise Ubiquitin
↑ Ub mRNA and protein 6 and 24 h KE — 7 sets×10 reps at 150% of 1-RM [64]
↑ Ub mRNA and protein 48 h KE — 7 sets×10 reps at 150% of 1-RM [76]
↑ Ub 48 h Dynamoter — 5 sets×53 reps [168]
↔ Ub-conjugated proteins 24 h LP — 3 sets×12 reps at 120% of 1-RM [71]
KE — 10 sets×10 reps at 120% of 1-RM
↑ Ub-conjugated proteins 48 h Dynamoter — 5 sets×53 reps [168]
20S proteasome
↑ 20S mRNA and protein 48 h KE — 7 sets×10 reps at 150% of 1-RM [76]
↑ HC2 and HC3 mRNA 6 and 24 h KE — 7 sets×10 reps at 150% of 1-RM [64]
↑ 20S protein 24 h KE — 7 sets×10 reps at 150% of 1-RM [64]
Ub-conjugating enzymes
↑ E2 mRNA and protein 6 and 24 h KE — 7 sets×10 reps at 150% of 1-RM [64]
↑ E2 mRNA and protein 48 h KE — 7 sets×10 reps at 150% of 1-RM [76]
Ub-ligase
↓ MAFbx/atrogin-1 3, 6 and 24 h 0.55 m step down every 2 s for 12 min [97]
Resistance exercise Ub-ligases
↑ MuRF1 mRNA 1–4 h KE — 3 sets×10 reps at 70% of 1-RM ⁎ [91]
↑ MuRF1 mRNA 2 h LP — 4 sets×10 reps at 80% of 1-RM [94]
↑ MuRF1 mRNA 4 h KE — 3 sets×10 reps at 70% of 1-RM [93]
↑ MuRF1 mRNA 4 h KE — 3 sets×10 reps at 65% of 1-RM [92]
↑ MuRF1 mRNA 24 h KE — 3 sets×10 reps at 70% of 1-RM ⁎ [91]
↔ MuRF1 mRNA 24 h KE — 3 sets×10 reps at 65% of 1-RM [92]
↔ MuRF1 mRNA 48 h LP — 4 sets×10 reps at 80% of 1-RM [94]
↑ MAFbx/atrogin-1 mRNA Immediately LE — 10 sets×10 reps at 80% of 1-RM [95]
↑ MAFbx/atrogin-1 mRNA 1–4 h KE — 3 sets×10 reps at 70% of 1-RM ⁎ [91]
↓ MAFbx/atrogin-1 mRNA 3 h LP — 8 sets×5 reps at 80% of 1-RM [98]
↔ MAFbx/atrogin-1 mRNA 3 h LE — 8 sets×5 reps at maximal effort [96]
↔ MAFbx/atrogin-1 mRNA 4 h KE — 3 sets×10 reps at 70% of 1-RM [93]
↔ MAFbx/atrogin-1 mRNA 4 h KE — 3 sets×10 reps at 65% of 1-RM [92]
↓ MAFbx/atrogin-1 mRNA 6 h 0.55 m step up every 2 s for 12 min [97]
↔ MAFbx/atrogin-1 mRNA 8–24 h KE — 3 sets×10 reps at 70% of 1-RM ⁎ [91]
↔ MAFbx/atrogin-1 mRNA 24 h KE — 3 sets×10 reps at 65% of 1-RM [92]
↓ MAFbx/atrogin-1 mRNA 24 h LE — 10 sets×10 reps at 80% of 1-RM [95]
↓ MAFbx/atrogin-1 mRNA 48 h LP — 4 sets×10 reps at 80% of 1-RM [94]
↔ MAFbx/atrogin-1 mRNA 72 h LE — 10 sets×10 reps at 80% of 1-RM [95]
Data obtained fromhuman studies investigating changes in skeletal muscle UPS components following acute eccentric or acute resistance exercise bouts in non-previously resistance
trained individuals. Time denotes period(s) elapsed from completion of exercise bout and recordedmeasurement. KE=Knee extension, LE=Leg extension, LP=Leg press,1-RM=1-Rep
max. ⁎=previously endurance trained.
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example, Willoughby et al. [64] showed greater increases in muscle
Ub protein content in healthy volunteers following the ﬁrst, rather
than a second eccentric exercise bout conducted 3 weeks apart.
Conversely, increased Ub-conjugation in skeletal muscle samples of
the vastus lateralis have been observed on the second of two exercise
sessions (involving eccentric leg press and knee extension exercises)
separated by N5 weeks [71]. Thus, further work is required to
rationalise these two observations and determine the involvement
of the UPS in this adaptive response. It also seems that to provide
meaningful information these experiments need to be performed in
conjunction with measurements of muscle protein turnover.
The signal(s) responsible for instigating increased skeletal muscle
UPS-mediated proteolysis following eccentric exercise are currently
unknown, but the cytokines have garnered much attention. Exercise
induced muscle damage is known to stimulate an acute phase
inﬂammatory response resulting in the inﬁltration of neutrophils
and macrophages into skeletal muscle [60]. Indeed, a single bout of
eccentric exercise is known to increasemacrophage counts per surface
unit of tissue in skeletal muscle compared to controls [71]. Moreover,
downhill running, which requires extensive eccentric contractions of
the vastus lateralis muscle, results in localised elevations of TNFα and
interleukin-6 (IL-6) mRNA and induces substantial muscle damage
[79]. Interestingly, contracting skeletal muscle is one of themajor sites
of IL-6 production [70], however, the source of the elevated TNFα is
less clear but is most likely to be macrophage-derived. Given that both
TNFα and IL-6 are capable of inducing muscle atrophy [49,80–83] and
of activating the UPS [49,84,85], it is tempting to suggest that theymay be involved in the instigation of the remodelling process
following eccentric damage. However, no evidence in humans yet
exists to conﬁrm these postulations. Moreover, given that eccentric
exercise contractions often result in only a small percentage of
severely damaged ﬁbres and yet global reduced rates of glucose
uptake to the order of 20–30% are observed, a systemic factor may be
responsible for the events that follow eccentric-induced muscle
damage [86–88].
3.2. Resistance training induced muscle mass gains
Heavy resistance training can induce substantial increases in muscle
mass, predominantly the result of increases in ﬁbre cross-sectional area
(hypertrophy) as opposed to ﬁbre number (hyperplasia). Moreover,
resistance training can increase the cross-sectional area of all three
major ﬁbre types (I, IIa and IIb), with a 20-week training program
sufﬁcient to increase the cross-sectional areas of type IIab and IIb ﬁbres
by 47%, type IIa by 39% and type I by 17% [89]. The hypertrophic
response to strength training appears predominantly the result of
enhanced rates of muscle protein synthesis simultaneous to increases in
muscle protein breakdown, albeit the change in the latter being of
smaller magnitude than the former thus leading to an overall positive
accumulation of muscle protein content [90]. Two groups have reported
an elevation of MuRF1 mRNA levels up to 24 h [91–94], and MAFbx/
atrogin-1 mRNA levels up to 4 h [91,95], following the induction of an
acute bout of resistance exercise (Table 1). However, mRNA quantiﬁca-
tion of the atrogenes a few hours subsequent to these measurements
have shown either reduced or basal levels [91–98]. Collectively, these
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fractional breakdown rate of skeletal muscle proteins 3 h post-
resistance exercise, declining to an 18% increase by 24 h, and a return
to resting values by 48 h [59]. The transient elevation of the fractional
breakdown rate concomitant to an increase in MuRF1 and MAFbx/
atrogin-1 mRNA levels is consistent with the suggestion that the
enhanced leg proteolysis observed is in part MAFbx/atrogin-1 and
MuRF1 dependent. However, measurements of the protein expression
for the two atrogins are currently lacking and would represent a
necessary prerequisite, in conjunction with the simultaneous determi-
nation of muscle protein breakdown, in conﬁrming this hypothesis.
The above ﬁndings are largely based on studies involving a single
bout of resistance exercise in previously untrained, recreationally
active individuals. The response to a regular and progressive
resistance exercise protocol is likely to differ. Chronic resistance
exercise is known to elicit a signiﬁcant increase in the proportion of
type IIa ﬁbres [89]. Moreover, greatest increases in MAFbx/atrogin-1
mRNA levels appear to occur in slow-twitch ﬁbres following
resistance exercise in humans (4 h and 24 h post-exercise; [92]),
suggesting that the purported rise in MAFbx/atrogin-1 and MuRF1
mediated protein breakdown following resistance exercise represents
a remodelling stimulus driving a change in ﬁbre-type expression to
that of a faster phenotype. Despite the extensive remodelling that
occurs following a chronic resistance exercise regime, levels of
MAFbx/atrogin-1 protein and MuRF1 mRNA remain elevated [99].
The consequences of the sustained elevation of the atrogins in
response to chronic resistance exercise remains unknown, although
suggestions levied of an increased basal rate of protein breakdown in
the context of increased protein turnover remain speculative in the
absence of measures of muscle protein turnover itself.
Increases in muscle protein synthesis are observed hours after a
bout of resistance exercise paralleled by increases in the phosphor-
ylation state of key components of the insulin-signalling pathway, in
most cases including AKT [100]. However, two recent reports have
suggested that the association between factors of translation initiation
and muscle protein synthesis in the human may be complex, where
changes in phosphorylation state of key members of translation
initiation, including AKT, GSK3β and mTOR, appear not to mirror
changes in leg protein synthesis [101,102], reinforcing the requirement
of measures of muscle protein turnover in study designs. What is also
not clear is the impact of Foxo inhibition (phosphorylation) by AKT on
MAFbx/atrogin-1 and MuRF1 transcription in human skeletal muscle
under conditions of resistance exercise. While reports in animals and
C2C12 myotubes would suggest a pivotal role for this pathway in the
control of MAFbx/atrogin-1 and MuRF1 expression [103,104], and by
association, muscle protein breakdown in the initial hours following
resistance exercise, its role in humans would appear modest. Indeed,
given the discord reported between the mRNA levels of the two
atrogenes [91–94] and the independent but contradictory reports of
transient increases in expression of both Ub-ligases in the face of AKT
activation following resistance exercise, other regulatory mechanisms
are likely to dominate in human skeletal muscle. Intriguingly, an early
increase in p38 MAPK by resistance exercise has been observed [95]
which, in conjunction with localised muscle inﬂammation and NF-κB
activation [105], could represent the primary elements responsible for
exercise-induced expression of the atrogenes and thus, the early
protein breakdown component of exercise.
However, skeletal muscle contraction also induces a marked ele-
vation in plasma IL-6 [106]. Moreover, the degree of IL-6 expression is
dependent on the intensity, duration and mode of the exercise [107]
and appears muscle derived [108]. Interestingly, exercise also results
in increased circulating levels of anti-inﬂammatory cytokines and the
inﬂammatory cytokine inhibitors, IL-1 receptor antagonist and
soluble TNFα receptors [106,109,110]; only very intense exercise
stimulates TNFα expression [111]. In addition, IL-6 is typically the
ﬁrst cytokine to appear in the circulation during exercise and showsthe most marked expression amongst the elevated cytokines. Intrigu-
ingly, treatment of cachectic murine colon adenocarcinomawith anti-
mouse IL-6 antibody was successful at ablating the skeletal muscle
atrophy commonly observed [112]. Furthermore, in C2C12 myotubes,
IL-6 shortens the half-life of long-lived proteins [113]. Concordantly,
transgenic mice overexpressing IL-6 experience profound muscle
atrophy and elevated Ub gene expression, which is preventable by the
administration of an IL-6 receptor antagonist [85]. Therefore, the
exercise-induced expression of IL-6 could, tentatively, represent an
alternative stimulus following resistance exercise for the early
elevation in the UPS.
4. UPS in muscle atrophy conditions in humans
Skeletal muscle comprises ∼40% of the total body mass of an
average adult human and has energy requirements even at rest.
Moreover, the inherent structure of skeletal muscle represents a
substantial reservoir of protein that can be utilised by hepatic tissue
during times of stress [114]. During periods of prolonged inactivity or
disease, a substantial reduction in muscle mass is commonly
observed, reducing total muscular energy requirements and, during
disease, providing substrates for hepatic gluconeogenesis and acute
phase protein production [114]. Despite these beneﬁcial features, a
dramatic loss of skeletal muscle mass can be debilitating, resulting in
prolonged times to recovery, increased risk of subsequent injury and a
severe burden on health care provisions. Pathological and environ-
mental states that can induce skeletal muscle atrophy can be broadly
divided into those with and without an inﬂammatory stimulus.
Examples of the former include bed rest/immobilisation, spinal cord
injury and fasting; whilst states with an inﬂammatory element
include cancer, AIDS, sepsis and perhaps sarcopenia in the frail
elderly. Despite both cohorts experiencing skeletal muscle atrophy,
the mechanistic events between groups most likely differ and are
examined in detail below.
4.1. Non-inﬂammatory skeletal muscle atrophy
Muscle disuse through limb immobilisation, bed rest or spinal
cord injury represent the majority of non-inﬂammatory related
atrophy seen in the clinical setting, and the degree of muscle loss can
be appreciably large. Indeed, two weeks of leg-immobilisation has
been shown to result in an almost 5% reduction in quadriceps lean
mass and a 27% fall in isometric strength [4]. Likewise, a 20%
reduction in type I muscle ﬁbre cross sectional area and a 30%
reduction in type II ﬁbre area, has been observed following 60-days
bed rest [115]. While elements of the UPS, notably levels of
ubiquitinated proteins [116] and HC6 mRNA [4], appear elevated
during disuse, a consistent elevation of MAFbx/atrogin-1 and MuRF1
mRNA has not been observed in human skeletal muscle in the studies
performed to date (Table 2). While some reports have detailed an
increase in MAFbx/atrogin-1 [4,116,117] mRNA to disuse stimuli in
humans, a number have reported no change or a reduction in the
mRNA levels of MAFbx/atrogin-1 [6] or MuRF1 [4,6,115,116]. In
comparison, a classical elevation of the atrogenes has been observed
in animals following denervation [42], hind limb suspension [42], or
space-ﬂight [118]. Numerous explanations exist for the disparity
between animal models of disuse, where large and consistent
elevations in expression of the atrogenes have been observed, and
humans, where variable ﬁndings in regard to MAFbx/atrogin-1 and
MuRF1 levels have thus far been reported. Most notable is the
generally greater severity of the procedures performed on animals to
induce muscle disuse compared to that employed in human
volunteers/patients. Furthermore, with the desire to limit invasive
procedures in humans, the number of muscle biopsies performed to
obtain tissue is usually minimised; as a consequence, a comprehen-
sive examination of the temporal expression of the atrogins in
Table 2
The UPS in inﬂammatory and non-inﬂammatory states characterised by muscle atrophy
Measured variable Condition Muscle Study
Non-inﬂammatory Ubiquitin
↑ Ubiquitinated proteins 20-day bed rest VL [116]
↓ Ubiquitylation rate Primary operative fracture repair (within 8 h of fracture) Various [169]
20S Proteasome
↑ HC6 mRNA 14–day leg immobilisation VL [4]
↓ TPP II mRNA 10–21 day immobilisation VL [6]
Ub-conjugating enzymes
↓ E2D3 Conjugating enzyme Ankle fracture (4–11 days immobilisation) GAS [117]
↓ E2N Ankle fracture (4–11 days immobilisation) GAS [117]
Ub-ligases
↑ Cbl-b mRNA 20-day bed rest VL [116]
↔ E3 ligase mRNA 14-day leg immobilisation VL [4]
↔ MAFbx/atrogin-1 mRNA 0–10 day immobilisation VL [6]
↑ MAFbx/atrogin-1 mRNA Ankle fracture (4–11 days immobilisation) GAS [117]
↓ MAFbx/atrogin-1 mRNA 10–21 day immobilisation VL [6]
↑ MAFbx/atrogin-1 mRNA 14-day leg immobilisation VL [4]
↑ MAFbx/atrogin-1 mRNA 20-day bed rest VL [116]
↑ MuRF1 mRNA 0–10 day immobilisation VL [6]
↓ MuRF1 mRNA 10–21 day immobilisation VL [6]
↔ MuRF1 mRNA 14-day leg immobilisation VL [4]
↔ MuRF1 mRNA 20-day bed rest VL [116]
↔ MuRF1 protein 60-day bed rest VL [115]
↑ MuRF1 protein 60-day bed rest SOL [115]
Inﬂammatory Ubiquitin
↑ Ubiquitin protein Critical illness; 1–25 days after ICU admission (APACHE 8–31) TA [148]
↑ Ubiquitin mRNA Cancer patients pre-op RA [170]
↑ Ubiquitin mRNA Cancer patients pre-op RA [139]
↑ Ubiquitin mRNA Cancer patients pre-op RA [140]
↑ Ubiquitin mRNA Septic patients undergoing abdominal surgery RA [147]
↑ Ubiquitin mRNA Severe head trauma (Glasgow score 3–8) VL [150]
↑ UbB polyubiquitin mRNA Multiple injury; 8–12 days after trauma (APACHE II 15±3) VL [149]
20S Proteasome
↑ HC3, HC5, HC7 and HC9 mRNA Cancer patients pre-op RA [170]
↑ HC2 and HC5 mRNA Cancer patients pre-op RA [138]
↑ HC2 and HC8 mRNA Severe head trauma (Glasgow score 3-8) VL [150]
↔ HC8 protein COPD patients undergoing thoractomy for lung cancer D [153]
↑ HC3 mRNA Septic patients undergoing abdominal surgery RA [147]
↑ Chymotrypsin-like activity COPD patients undergoing thoractomy for lung cancer D [153]
↑ Chymotrypsin-like activity Cancer patients pre-op RA [140]
↑ Trypsin-like activity Cancer patients pre-op RA [140]
↑ Peptidylglutamyl peptide-hydrolyzing activity COPD patients undergoing thoractomy for lung cancer D [153]
↑ Peptidylglutamyl peptide-hydrolyzing activity Cancer patients pre-op RA [140]
Ub-conjugating enzymes
↑ E214K Severe head trauma (Glasgow score 3–8) VL [150]
Ub-ligases
↑ MAFbx/atrogin-1 mRNA COPD patients undergoing thoractomy for lung cancer D [153]
↑ MAFbx/atrogin-1 mRNA Acute quadriplegic myopathy VL [151]
↑ MAFbx/atrogin-1 mRNA COPD patients VL [152]
↑ MAFbx/atrogin-1 mRNA ALS patients B/VL [126]
↔ MAFbx/atrogin-1 protein COPD patients VL [152]
↑ MAFbx/atrogin-1 protein ALS patients B/VL [126]
↑ MuRF1 mRNA COPD patients VL [152]
↔ MuRF1 mRNA COPD patients undergoing thoractomy for lung cancer D [153]
↔ MuRF1 mRNA ALS patients B/VL [126]
Data obtained fromhuman studies investigating changes in skeletal muscle UPS components following non-inﬂammatory and inﬂammatory states of muscle atrophy. COPD=Chronic
obstructive pulmonary disease, ALS=Amyotrophic lateral sclerosis; VL=Vastus lateralis, GAS=Gastrocnemius, SOL=Soleus, TA=Tibialis Anterior, RA=Rectus abdominus, B=Bicep,
D=Diaphragm.
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after onset, is currently lacking. A lone report examining temporal
levels of MAFbx/atrogin-1 and MuRF1 mRNA reinforces the need for
such work to be undertaken as a matter of course. de Boer et al. [6]
showed 10 days limb immobilisation to result in elevated mRNA
levels for MuRF1, but not MAFbx/atrogin-1, in the vastus lateralis of
healthy human volunteers; however, 11 further days of limb
immobilisation saw a subsequent fall in mRNA levels for both
atrogenes. Given these shortcomings which, in conjunction with a
general absence of data on the protein expression of the two atrogins
(with the exception of [115]), it is not currently possible to discern
the functional relevance of MAFbx/atrogin-1 and MuRF1 to the
human condition of muscle disuse atrophy. The lack of protein levelsof the atrogins is particularly pertinent given the recent observations
of Vary et al. [119] who demonstrated acute alcohol intoxication in
rodents to increase MAFbx/atrogin-1 and MuRF1 mRNA levels
without resulting in a concomitant rise in muscle proteolysis. Such
observations could suggest that MAFbx/atrogin-1 and MuRF1 do not
necessitate muscle protein breakdown; but without direct measures
of MAFbx/atrogin-1 and MuRF1 protein levels, it is difﬁcult to
ascertain the true signiﬁcance of such ﬁndings. However, it should be
noted that a few reports of muscle proteolysis occurring indepen-
dently of changes in MAFbx/atrogin-1 and/or MuRF1 mRNA levels
have recently been published, which would question the role of the
atrogins in muscle proteolysis [50,119–121]. Further work is required
to rationalise these important observations.
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animals following unloading [118,122], have been tentatively linked to
disuse atrophy. Preliminary evidence from humans has shown a
statistically signiﬁcant, albeit small (∼2.5-fold increase compared to
controls) rise in Cbl-b, but not Siah-1 A, mRNA levels following disuse
atrophy [116]; whilst the involvement of Nedd4 in muscle atrophy
remains to be examined in human skeletal muscle. Thus, an
examination of the involvement of Cbl-b and Nedd4 in the induction
of disuse atrophy iswarranted. Interestingly, a target of Cbl-b Ub-ligase
activity includes growth factor receptors, possibly including IRS-1
[116]. Furthermore, with a bona-ﬁde target of Nedd4 being Notch1, a
protein associated with satellite cell proliferation and differentiation
[122], the further study of both Ub-ligases appears judicious.
The advent and adoption of microarray technology has allowed the
rapid identiﬁcation of global changes in gene expression following an
applied intervention and represents a valuable approach, particularly
when integrated with functional measurements in a time-dependent
experimental paradigm. However, to date, only a handful of human
studies investigating muscle atrophy events have adopted the
microarray approach. Despite this, several novel observations related
to proteins associated with the UPS have been observed in three
differing models of human muscle disuse atrophy. Firstly, in the
immediate days following spinal cord injury (2 and 5 days from injury)
increased expression changes in Ub E3-ligase C and the 26S
proteasome non-ATP-ase regulatory subunit 11 has been revealed
using the Affymetrix GeneChip approach [123]. Furthermore,
increases in the Ub-conjugating enzyme, UBE2E, as well as the Ub-
ligase, FBXO9, have been identiﬁed in muscle biopsies following limb
immobilisation [124]. These immobilisation-induced changes were in
addition to elevations in USP-6, a deubiquitinating-enzyme respon-
sible for cleaving Ub from Ub tagged proteins, thereby purportedly
allowing efﬁcient recycling of Ub monomers during catabolic states,
and SUMO-1, a small Ub modiﬁer, previously postulated to prevent
UPS-mediated protein degradation of conjugated proteins [124,125].
Lastly, 4–11 days of cast mediated immobilisation following ankle
fracture resulted in 227 genes being differentially expressed compared
to muscle from healthy control subjects prior to cast mediated
immobilisation, with all bar 26 genes downregulated [117]. Interest-
ingly, 96% of the transcriptional changes that occurred following limb
immobilisation in ankle fracture patients were also observed in the
contralateral leg of the patients, but these changes were not observed
in the non-immobilised limb from cast-immobilised healthy volun-
teers [117]. Although perplexing, it is possible that the observed
transcriptional changes in the contralateral leg of ankle fracture
patients may be due to increased bed rest/decreased mobility
following ankle fracture, highlighting the additional complexity of
studying patient populations where a component of the observed
muscle atrophy could be due to decreased activity levels [117].
However, elevated levels of MAFbx/atrogin-1 was only observed in
samples isolated from patients with ankle fractures, an observation
that is supportive of its role as a regulator of muscle atrophy; although
in contrast, other members of the UPS such as E2D3 and E2N were
downregulated in the muscle of ankle fracture patients when
compared to healthy control subjects prior to cast mediated
immobilisation [117].
With two notable exceptions [115,126], the general absence of
protein measurements for the two atrogins is concerning and
introduces compounding issues in the interpretation of current
mRNA data for the role of the UPS in muscle atrophy. Interestingly,
it has been suggested that the loss of lean body mass observed
following disuse induced muscle atrophy in the human is primarily
the result of a decrease in muscle protein synthesis [127]. Reductions
in muscle protein synthesis following disuse atrophy have been
reported by several groups, despite the maintenance of adequate
nutritional intake [128,129]. de Boer et al. [6] detected a 50% reduction
in myoﬁbrillar protein synthesis after 10 days of limb suspension,which was similarly suppressed 11 days later. They approximated that
if daily mixed muscle protein synthesis fell by 50% to 1.0–1.25% per
day, protein breakdown rates would not need to be elevated above the
basal rate of 2.0–2.5% per day to account for the 0.5% fall per day in
cross sectional area. However, given the existence of the purported
AKT/Foxo/atrogene axis [103,104], this observation of a marked
reduction in muscle protein synthesis during human limb immobili-
sation cannot be easily reconciled with the proposal of unchanged
muscle protein breakdown and moreover, is not in concordance with
experimental observations of increased muscle protein breakdown in
animals following either denervation [130], hindlimb suspension
[131] or limb immobilisation [132]. In reality, evidence of changes in
muscle protein degradation in humans over the time-course of muscle
disuse remains to be demonstrated and represents an essential
component in the determination of the true signiﬁcance of UPS-
mediated degradation during immobilisation induced atrophy.
Despite the aforementioned scepticism held by some in regard to
the role of muscle protein breakdown in human muscle disuse,
confocal microscopy of vastus lateralis muscle samples taken after 60-
days bed rest has revealed MuRF1 immunoreactivity in the cytosolic/
myoﬁbrillar compartment of myoﬁbres, with strong cytosolic immu-
noﬂuorescence in subpopulations of atrophicmyoﬁbres [115]. Further-
more, work emanating from our group has shown the suppression of
limb protein breakdown that occurs following intravenous amino acid
infusion during periods of elevated serum insulin (30mU l−1), occur in
conjunction with a fall in MAFbx/atrogin-1 and proteasome subunit
HC2 protein levels, suggesting that MAFbx/atrogin-1 may in part be
responsible for increasedmuscle protein breakdown in humanmuscle
[102]. Notwithstanding where measurements of muscle protein
breakdown remain outstanding, such observations would be in
agreement with suggestions that the atrogins play a role in the loss
ofmusclemass during disuse, possibly by regulating cellular signalling
mechanisms. Ubiquitin tagging and/or UPS-mediated degradation has
long been considered a viable mechanism in the regulation of distinct
pathways, as observed in the regulation of NF-κB activity by IκB (for a
review see [133]). Interestingly, reduced muscle protein synthesis
following amino acid deprivation has been observed in wild-type but
not MuRF1−/− mice implicating MuRF1 as a negative regulator of
muscle protein synthesis [134]. This is further reinforced by reports of
MuRF1−/− MuRF2−/− mice displaying signiﬁcant muscle hypertrophy
and elevated levels of p70S6K in its active form, but notably, without
changes in total levels of multiubiquitinated proteins and thus,
presumably, degradation [137]. These ﬁndings, in conjunction with
the currently known targets of the atrogins, which in skeletal muscle
include MyoD [135] and eIF3f [136] for MAFbx/atrogin-1, and myosin
heavy chain [47], creatine kinase [134] and possibly the myoﬁbrillar
proteins titin, nebulin and myosin light chain-2 [137] for MuRF1,
suggest that in addition to proteolysis of myoﬁbrillar proteins, the
atrogins may also be responsible for suppressing anabolic and
hyperplastic signals, including muscle protein synthesis. While the
extent towhich these ﬁndings are applicable to human skeletalmuscle
is unknown, it is intriguing to note that such observations are
compatible with current reports in humans, although they do not
explain why elevations in MAFbx/atrogin-1 and MuRF1 are not
consistently observed in all models of disuse, though this could simply
be due to the timing of muscle sampling failing to coincide with
transient elevations of the atrogenes and/or that only transcriptional
changes in the atrogenes have mainly thus far been examined. Work
examining the temporal expression of the atrogins (mRNA and
protein) during disuse in conjunction with measurements of protein
degradation in humans should resolve this conundrum.
4.2. Inﬂammatory-mediated atrophy
Many disease states that are characterised by systemic inﬂamma-
tion are also associated with a muscle mass deﬁcit, which can have a
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disease states also display increased levels of both UPS components
and the two atrogenes (Table 2). Interestingly, mRNA levels for
proteasomal subunits and Ub, in addition to proteasomal chymotryp-
sin-like activitymeasured inmuscle samples of patients suffering from
cancer, appear greatest in individuals experiencing signiﬁcant weight
loss [138–140]. Moreover, mRNA levels of proteasomal subunits HC2
and HC5 in cancer cachectic patients appeared dependent on the
degree ofweight loss [138]. Patients experiencing aweight loss greater
than 10%, where muscle protein content starts to become signiﬁcantly
depressed, show a parabolic relationship between the two subunits
and weight loss; with HC2 and HC5 mRNA increasing maximally for
patients with 12–19%weight loss and declining levels thereafter [138].
Likewise, the Ub-conjugating enzyme E214K also showed a similar
parabolic relationship with weight loss as the two proteasomal
subunits [138]. Importantly, signiﬁcantly higher circulating levels of
both IL-6 and C-reactive protein (CRP), an acute phase protein
commonly employed as a marker for the magnitude of systemic
inﬂammation, have been observed in weight-losing cancer patients
compared to cancer patients without weight loss [141]. Furthermore,
plasma levels of CRP and IL-6 appeared to correlate with skeletal
muscle Ub mRNA levels in weight losing cancer patients [142]; while
gastrointestinal cancer patients receiving the anti-inﬂammatory
compound, ibuprofen, in conjunction with an appetite stimulator
(megestrol acetate), demonstrated signiﬁcant improvements in
weight, mid-upper arm circumference and quality of life scores
compared to patients receiving megestrol acetate alone, independent
of changes in appetite [143]. Collectively, these ﬁndings would suggest
that in cancer cachexia, the UPS is actively involved in the initial stages
of muscle protein loss and furthermore, implicate the associated
inﬂammatory response as a potential regulator of the catabolic
processes underlying cancer cachexia.
Inﬂammatory states result in the systemic production of a multi-
tude of inﬂammatory and anti-inﬂammatory cytokines. Moreover, the
cytokine response observed differs from that elicited by exercise,
where increases in TNFα and IL-1β are generally not observed [144].
Interestingly, numerous reports have demonstrated that the cytokines
are capable of eliciting UPS-mediated protein degradation in skeletal
muscle (for a review see [145]). Thus, a purported cytokine induction of
the UPS could be responsible for the observed differences between
disuse and inﬂammatorymediatedmuscle loss. However, determining
causality for the cytokines in inﬂammatory states, especially in
humans, remains particularly problematic.
Induction of the UPS has also been documented in the skeletal
muscles of patients admitted to Intensive Care Units (ICU), a
subpopulation of patients that often present with pronounced
inﬂammatory responses [146]. In muscle samples from septic patients
obtained during abdominal surgery, an elevation in mRNA levels for
Ub and proteasomal subunit HC3 was detected [147]. In a subsequent
study which utilised patients representing a larger spectrum of
admissions to the ICU, including individuals suffering from sepsis,
vascular disease or road trafﬁc accident trauma, a mean daily decrease
in cross sectional area of 4% for type II and 3% for type I ﬁbres was
observed in addition to an overall increase in Ub protein levels [148].
Furthermore, a separate study of ICU patients detailed a signiﬁcant
positive correlation between the levels of UbB polyubiquitin mRNA
and the rate of protein degradation 8–12 days after admission, as
determined by the rate of intracellular phenylalanine appearance by
the isotope dilution technique [149], with the authors concluding that
the rate of proteolysis after trauma is mainly regulated at the level of
transcription. Additionally, these ﬁndings are in concordance with the
work by Mansoor et al. [150], who demonstrated signiﬁcantly
increased mRNA levels of Ub, E214K and HC2 in head trauma patients
presenting with negative nitrogen balance and indices of increased
protein breakdown (endogenous leucine production). Lastly,
increased levels of MAFbx/atrogin-1 mRNA has been observedfollowing acute quadriplegic myopathy, a subacute muscle disorder
characterised by generalised progressive muscle weakness and
atrophy that is predominantly associated with a patient history of
sepsis, multiple organ failure, surgery and intensive care admission
[151]. Collectively, these ﬁndings highlight the catabolic consequences
of trauma in its various forms and demonstrate evidence that the
reductions in muscle protein content are, at least in part, mediated via
the actions of the UPS. However, a spectrum of critically ill patients
will likely contain a host of different clinical presentations, each able
to modify the catabolic response. Such possible inﬂuences include
massive systemic inﬂammation, starvation, immobilisation, insulin
resistance and denervation. This represents a limitation in the ability
to determine the primary initiator of the catabolic response when
utilising patient populations, if indeed such a thing exists.
Unfortunately, the number of studies that have examined the
transcriptional changes of the two atrogenes in human inﬂammatory
states is severely limited. While elevations in MAFbx/atrogin-1 mRNA
have been observed in amyotrophic lateral sclerosis patients [126],
conﬂicting results have been observed in chronic obstructive
pulmonary disease (COPD) sufferers, where reports of both an
elevation [152] and no signiﬁcant change [153] in the level of the
Ub-ligase have been reported (Table 2). However, where elevations in
MAFbx/atrogin-1 mRNA have been reported, they do not appear to
have led to increased levels of the MAFbx/atrogin-1 protein [152].
Furthermore, elevations of MAFbx/atrogin-1 mRNA were also not
observed in the muscles of either old adults (N60 yrs; [154]) or very
old women (∼85 yrs; [93]). Similarly, inconsistent ﬁndings for MuRF1
mRNA levels have been observed in COPD sufferers, with both
increased [152] and basal [153] levels of MuRF1 mRNA reported.
Increased MuRF1 mRNA levels have been observed in elderly women
(∼85 yrs; [93]), but no change recorded in either amyotrophic lateral
sclerosis patients [126]) or elderly adults (N60 yrs; [154]). However,
given that the age-dependent loss of skeletal muscle mass (sarcope-
nia) is thought to be predominantly due to the resistance of skeletal
muscle protein synthesis to circulating amino acids [155], it is not
surprising that a robust induction of MAFbx/atrogin-1 andMuRF1was
not observed in elderly individuals. Taken together, it is difﬁcult from
the limited evidence available to determine if MAFbx/atrogin-1 and
MuRF1 have an active role in the UPS-mediated degradation of muscle
proteins during inﬂammatory diseases. Given the robust induction of
the UPS in ICU and cancer cachectic patients, it may be that the study
of more acute and extreme inﬂammatory states, as seen in sepsis [7]
and following burn-injury [156], may provide greater insight into the
purported roles of the two atrogins in humans. It is noteworthy that
both sarcopenic and COPD patients have been reported to present
with systemic low grade inﬂammation [157–159] and, arguably in
COPD patients, the localised levels of cytokines in the hindlimb
muscles may not be notably elevated compared to controls [160].
Indeed, components of the UPS in chronic conditions such as
Cushing's syndrome and Duchenne muscular dystrophy are known
to be unchanged compared to acute catabolic states [161].
Interestingly, where increases in atrogene mRNA levels have been
reported in the skeletal muscle of COPD sufferers, a parallel increase in
skeletal muscle cytoplasmic protein content of phosphorylated AKT
simultaneous to an increase in both Foxo1 mRNA expression and
Foxo1 protein levels present in the nucleus have also been recorded
[152]. Likewise, enhanced MAFbx/atrogin-1 mRNA and protein levels
in amyotrophic lateral sclerosis sufferers occurred in conjunctionwith
a fall in AKT phosphorylation, but no change in the nuclear protein
content of Foxo1 or Foxo3 [126]. Therefore, in contrast to a proposed
regulation of MAFbx/atrogin-1 and MuRF1 transcription by an AKT-
forkhead transcription factor axis (Fig. 2) [103,104], the expression of
the two atrogenes appears to be dependent on another mechanism, at
least in COPD or amyotrophic lateral sclerosis patients. The observa-
tion of a discord in the relationship between AKT and Foxo proteins is
not without precedent. In human primary breast tumours lacking a
739A.J. Murton et al. / Biochimica et Biophysica Acta 1782 (2008) 730–743detectable phosphorylated AKT protein, Foxo3 was predominantly
conﬁned to the cytoplasm as opposed to the nucleus [162]. Reasons for
this remain unclear.
5. Involvement of the UPS in exercise rehabilitation
For numerous years, exercise has been prescribed as an essential
element of the rehabilitation program for individuals followingFig. 3. Effect of leg immobilisation and rehabilitation on the UPS andmuscle mass. Twoweeks
on: (A) mRNA expression of 20S (closed diamonds), ubiquitous E3 ligase (closed circles), M
MuRF1 mRNA levels); (B) Change in quadriceps lean mass compared to basal. Bars/lines s
immediately post-immobilisation; signiﬁcance deﬁned at pb0.05. (C) Representative DEXA im
permission.muscle atrophy. A limited number of studies have examined the
changes that occur in the UPS following the induction of exercise-
mediated rehabilitation. For example, our laboratory has shown
6 weeks of resistance exercise training to be sufﬁcient to reverse the
∼5% fall in quadriceps lean mass observed after two weeks leg
immobilisation ([4]; Fig. 3). Moreover, 24 h following cast removal and
the ﬁrst exercise session, mRNA levels of both atrogenes were
decreased, returning to basal levels when compared to immediatelyleg immobilisation and 6weeks isokinetic rehabilitation exercise in healthy youngmen
AFbx (open triangles), and MuRF1 (open circles, p=0.1 for pre- vs. post-immobilisation
how mean±SEM; ⁎ signiﬁcantly different from basal; † signiﬁcantly differently from
ages localised to left leg pre- and post-immobilisation. Adapted from [4] and used with
740 A.J. Murton et al. / Biochimica et Biophysica Acta 1782 (2008) 730–743post-immobilisation. In addition, immobilisation induced mRNA
increases in 20S proteasome subunit HC6, returned to normal levels
1 week from the start of the exercise regime [4]. Likewise, a
combination of resistance exercises and aerobic exercises performed
on opposing days, at an interval of once every 3 days, was able to
prevent the increased protein expression of MuRF1 in soleus muscle
and maintain ﬁbre cross sectional area following 60-days bed rest
[115]. These observations, in conjunction with reports that passive leg
cycling in spinal cord injury patients signiﬁcantly reduced mRNA
levels of Ub, E2 and 20S [163], demonstrate that exercise is sufﬁcient
to blunt the UPS in human skeletal muscle following disuse atrophy.
Whilst the signiﬁcance of the exercise induced depression of UPS
components on protein content is unknown, it is interesting to note its
apparent relationship with the restoration of muscle mass.
Conversely, exercise (cycle ergometry) has been shown to
exacerbate the increased expression of UPS components in COPD
patients [164]. Such changes were not observed in healthy controls
undergoing the same training protocol [164]. Interestingly, the
pathophysiology of COPD could induce mild oxidative stress during
periods of exercise [165] and such conditions are known to be capable
of increasing the expression of UPS components [166]. However, it
should be noted that it is unequivocal that endurance training
improves exercise capacity, muscle force, quality of life and functional
status of COPD sufferers [167].
6. Conclusions
In comparison to the wealth of knowledge from animal models
concerning the involvement of the UPS in skeletal muscle atrophy
and/or remodelling, studies in humans are at a comparatively early
stage, with most studies based predominantly upon the examination
of transcriptional events. However, initial ﬁndings would suggest that
signiﬁcant differences exist in themolecular events that underpin UPS
mediated protein degradation in animals and humans in response to
diverse stimuli. This is most notable in non-inﬂammatory conditions
of muscle atrophy, where the role of the UPS and that of the atrogins,
appear particularly exaggerated in animals compared to that observed
in humans, although this could merely be a reﬂection of the disparity
between the severity of animal and human models of muscle disuse.
Thus, in more global terms, the role of muscle protein breakdown in
these conditions remains equivocal. Furthermore, several discrepan-
cies in the proposed regulation of the atrogenes between animals/cell
lines and that of humans have started to emerge, suggesting
alternative regulatory pathways that have yet to be described.
Collectively, these ﬁndings highlight the pivotal importance for
detailed human studies in determining the pathways regulating
skeletal muscle mass in conditions of health and disease, utilising
temporal measures of muscle protein turnover and biomolecular
techniques across the spectrum of transcriptional, translational and
post-translational events.
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